Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in TaxesChange in TaxesChange in Working CapitalChange in Working CapitalDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet Income
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Capital Expenditures (2021 - 2024)

Trinity Biotech's Capital Expenditures history spans 6 years, with the latest figure at -$157000.0 for Q4 2024.

  • On a quarterly basis, Capital Expenditures rose 37.2% to -$157000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was -$1.0 million, a 13.97% increase, with the full-year FY2025 number at $88000.0, down 78.27% from a year prior.
  • Capital Expenditures hit -$157000.0 in Q4 2024 for Trinity Biotech, up from -$250000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for TRIB hit a ceiling of -$143.0 in Q2 2022 and a floor of -$570000.0 in Q4 2021.
  • Historically, Capital Expenditures has averaged -$237691.5 across 4 years, with a median of -$203500.0 in 2023.
  • The widest YoY moves for Capital Expenditures: up 63.24% in 2022, down 16.67% in 2022.
  • Tracing TRIB's Capital Expenditures over 4 years: stood at -$570000.0 in 2021, then increased by 16.67% to -$475000.0 in 2022, then soared by 47.37% to -$250000.0 in 2023, then soared by 37.2% to -$157000.0 in 2024.
  • Business Quant data shows Capital Expenditures for TRIB at -$157000.0 in Q4 2024, -$250000.0 in Q4 2023, and -$128000.0 in Q3 2023.